Burns - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H1 2017, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 2, 11, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Burns - Overview
Burns - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Burns - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Burns - Companies Involved in Therapeutics Development
AlgiPharma AS
Alliance Pharma Plc
Amarantus Bioscience Holdings Inc
American Gene Technologies International Inc
Biogenomics Ltd
CytoTools AG
Destiny Pharma Ltd
GangaGen Inc
Lakewood-Amedex Inc
Madam Therapeutics BV
Mallinckrodt Plc
MediWound Ltd
Mitochon Pharmaceuticals Inc
Phosphagenics Ltd
Se-cure Pharmaceuticals Ltd
USV Pvt Ltd
Burns - Drug Profiles
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-3APO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
albumin (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLO-ASC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AyuV-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bromelains - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Dermatology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epidermal growth factor biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMSP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neu-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nu-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligomer G for Burn Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silver sulfadiazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vanadis-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XF-70 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burns - Dormant Projects
Burns - Discontinued Products
Burns - Product Development Milestones
Featured News & Press Releases
Mar 03, 2017: Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid in Burn Management Published in BioMed Research International
Feb 09, 2017: Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area
Feb 06, 2017: MediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid Expanding Treatment of Severe Burns to Children Age One to Four
Aug 24, 2016: MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2016
Aug 08, 2016: Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
Jun 07, 2016: MediWound's NexoBrid Receives Reimbursement in Italy
May 19, 2016: MediWound's NexoBrid Highlighted in "Best Oral Presentation" at the British Burn Association 49th Annual Conference and Scientific Meeting
May 02, 2016: MediWound's NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting
Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized
Feb 22, 2016: Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program
Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters
Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania
Oct 31, 2015: Anterogen: Phase II IND Approval for "ALLO-ASC-BI"
Oct 26, 2015: Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Burns, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Burns - Pipeline by AlgiPharma AS, H1 2017
Burns - Pipeline by Alliance Pharma Plc, H1 2017
Burns - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
Burns - Pipeline by American Gene Technologies International Inc, H1 2017
Burns - Pipeline by Biogenomics Ltd, H1 2017
Burns - Pipeline by CytoTools AG, H1 2017
Burns - Pipeline by Destiny Pharma Ltd, H1 2017
Burns - Pipeline by GangaGen Inc, H1 2017
Burns - Pipeline by Lakewood-Amedex Inc, H1 2017
Burns - Pipeline by Madam Therapeutics BV, H1 2017
Burns - Pipeline by Mallinckrodt Plc, H1 2017
Burns - Pipeline by MediWound Ltd, H1 2017
Burns - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
Burns - Pipeline by Phosphagenics Ltd, H1 2017
Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H1 2017
Burns - Pipeline by USV Pvt Ltd, H1 2017
Burns - Dormant Projects, H1 2017
Burns - Dormant Projects, H1 2017 (Contd..1), H1 2017
Burns - Discontinued Products, H1 2017